1415994-42-1

Basic information

• Product Name: (1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)-ethanol
• Synonyms: (1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)-ethanol
• CAS NO: 1415994-42-1
• Molecular Weight: 344.194
• Mol File: 1415994-42-1.mol
• Article Data: 16

Chemical Properties

• CAS DataBase Reference: (1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)-ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: (1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)-ethanol(1415994-42-1)
• EPA Substance Registry System: (1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)-ethanol(1415994-42-1)

Safety Data

• Hazardous Substances Data: 1415994-42-1(Hazardous Substances Data)

Upstream product

• 1416002-35-1 (R,S)-(2-(3,5-dichloropyridin-4-yl)-1-(3,4-dimethoxyphenyl)ethyl)(R)-2-(6-methoxynaphthalen-2-yl)propanoate 
• 1416002-00-0 (S)-2-(3,5-dichloropyridin-4-yl)-1-(3,4-dimethoxyphenyl)ethanol ? 
• 100868-46-0 3,5-dichloro-4-picoline 
• 120-14-9 3,4-dimethoxy-benzaldehyde 

Relevant articles and documents

Discovery of M3Antagonist-PDE4 Inhibitor Dual Pharmacology Molecules for the Treatment of Chronic Obstructive Pulmonary Disease

In this paper, we report the discovery of dual M3 antagonist-PDE4 inhibitor (MAPI) compounds for the inhaled treatment of pulmonary diseases. The identification of dual compounds was enabled by the intuition that the fusion of a PDE4 scaffold derived from our CHF-6001 series with a muscarinic scaffold through a common linking ring could generate compounds active versus both the transmembrane M3 receptor and the intracellular PDE4 enzyme. Two chemical series characterized by two different muscarinic scaffolds were investigated. SAR optimization was aimed at obtaining M3 nanomolar affinity coupled with nanomolar PDE4 inhibition, which translated into anti-bronchospastic efficacy ex vivo (inhibition of rat trachea contraction) and into anti-inflammatory efficacy in vitro (inhibition of TNFα release). Among the best compounds, compound 92a achieved the goal of demonstrating in vivo efficacy and duration of action in both the bronchoconstriction and inflammation assays in rat after intratracheal administration.

HETEROARYL DERIVATIVES

Compounds of formula (I) described herein are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.

HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES

The invention relates to novel compounds of formula (I) which are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.